Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on June 14, 2011. The report serves as a Regulation FD disclosure regarding an update to the company's ongoing Phase I human clinical trial. The trial involves the company's spinal cord stem cells for the treatment of Amyotrophic Lateral Sclerosis (ALS) and is being conducted at Emory University in Atlanta, Georgia.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is the update on the status of the Phase I clinical trial for ALS treatment. No financial or operational changes compared to a prior period are detailed in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The company provided an update on the progress of its clinical trial via a press release attached as Exhibit 99.01.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the information is not "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. It explicitly notes that the information shall not be deemed an admission as to the materiality of any information within the report.
Key Facts for Investor Verification
- Verify the specific details of the Phase I clinical trial progress by reviewing the attached press release (Exhibit 99.01).
- Confirm the location of the trial is Emory University in Atlanta, Georgia.
- Note that this filing contains no financial data; investors should refer to the company's most recent 10-K or 10-Q for financial health metrics.
- Understand that the clinical trial update is for ALS (Lou Gehrig's disease) using spinal cord stem cells.